Evidence map›Paper›PMID 35371038›Full record

ArticleFrontiers in immunology2022

Genetic Variants of the

Christina-Maria Flessa, Evangelia Zampeli, Maria-Eleftheria Evangelopoulos, Vasilis Natsis, Iris L A Bodewes, Erika Huijser, Marjan A Versnel, Haralampos M Moutsopoulos, Clio P Mavragani

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Christina-Maria FlessaDepartment of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Evangelia ZampeliDepartment of Rheumatology, Iaso General Hospital, Athens, Greece.
Maria-Eleftheria Evangelopoulos1st Department of Neurology, Multiple Sclerosis and Demyelinating Disease Unit, Eginition University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Vasilis Natsis1st Department of Neurology, Multiple Sclerosis and Demyelinating Disease Unit, Eginition University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Iris L A BodewesDepartment of Immunology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, Netherlands.
Erika HuijserDepartment of Immunology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, Netherlands.
Marjan A VersnelDepartment of Immunology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, Netherlands.
Haralampos M MoutsopoulosChair Medical Sciences, Immunology, Academy of Athens, Athens, Greece.
Clio P MavraganiDepartment of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Erasmus MC · NLNational and Kapodistrian University of Athens · GRAcademy of Athens · GREginition Hospital · GRIASO General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Purpose: Primary Sjögren's Syndrome (SS) is characterized by B lymphocyte hyperactivity with B cell activating factor (BAFF) acting as an important regulator. Single Nucleotide Polymorphisms (SNPs) of the Methods: Fatigue status was assessed in 199 consecutive primary SS patients (Greek cohort) using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale. Clinical, histological, laboratory, psychometric and personality data were also collected. DNA extracted from peripheral blood of all patients underwent evaluation for the presence of five Results: TT genotype of the rs9514828 Conclusions: We report a novel association between genetic makeup and primary SS-associated fatigue with the rs9514828 TT genotype decreasing the likelihood of fatigue development among these patients. These findings need validation in multi-center studies.

Indexed as

B-Cell Activating FactorSjogren's SyndromeCase-Control StudiesGenetic Predisposition to DiseaseGenotypeHumansPolymorphism, Single NucleotideB-Cell Activating FactorTNFSF13B protein, humanBAFFfatiguers9514828single nucleotide polymorphisms (SNPs)Sjögren’s Syndrome

Identifiers

PMID35371038
PMCPMC8964489
OpenAlexW4220964186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.